Exploring the prevalence and burden of sleep disturbance in primary brain tumor patients.

Amanda L KingDorela D Shuboni-MulliganElizabeth VeraSonja CrandonAlvina A AcquayeLisa BorisEric BurtonAnna ChoiAlexa ChristEwa GrajkowskaVarna JammulaHeather E LeeperNicole LolloMarta Penas-PradoJennifer ReyesBrett TheelerKathleen WallJing WuMark R GilbertTerri S Armstrong

Published in: Neuro-oncology practice (2022)

PBT patients with moderate-severe SD are more symptomatic, have worse mood disturbance, and have several co-occurring symptoms. Targeting interventions for sleep could potentially alleviate other co-occurring symptoms, which may improve life quality for PBT patients. Future longitudinal work examining objective and detailed subjective sleep reports, as well as underlying genetic risk factors, will be important.

Keyphrases

sleep quality
risk factors
end stage renal disease
physical activity
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
gene expression
depressive symptoms
genome wide
cross sectional
cancer therapy
patient reported
adverse drug